Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Ardent Health, Inc. due to allegations of violations of federal securities laws related to misleading statements and undisclosed information regarding accounts receivable and revenue recognition [2][4]. Group 1: Allegations and Financial Impact - The complaint alleges that Ardent Health and its executives made false statements regarding the company's accounts receivable and the processes used to determine their collectability [4]. - On November 12, 2025, Ardent Health disclosed a $43 million decrease in third quarter 2025 revenue, attributed to revised determinations of accounts receivable collectability following a transition to a new revenue accounting system [4]. - The new accounting system, Kodiak RCA net revenue platform, allowed for more precise determination of accounts receivable collectability, leading to earlier recognition of reserves compared to the previous framework [4]. - Ardent Health also reduced its 2025 EBITDA guidance by approximately 9.6%, from a range of $575 million - $625 million to $530 million - $555 million, citing persistent industry-wide cost pressures [4]. - Following this announcement, Ardent Health's stock price fell by nearly 34%, from $14.05 to $9.30 per share on November 13, 2025, on unusually heavy trading volume [4]. Group 2: Legal Proceedings and Investor Actions - Investors who purchased or acquired securities in Ardent between July 18, 2024, and November 12, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal rights and options [1][2]. - There is an April 21, 2026, deadline for investors to seek the role of lead plaintiff in the federal securities class action filed against Ardent [2][5]. - The lead plaintiff is defined as the investor with the largest financial interest in the relief sought by the class, who will oversee the litigation on behalf of the class members [5].

NEW YORK, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP reminds purchasers or Ardent, Inc. (NYSE: ARDT) (“Ardent”) that a federal securities class action has been filed on behalf of investors who purchased Ardent between July 18, 2024 and November 12, 2025, inclusive (the “Class Period”). Investors have until March 9, 2026 to seek appointments as lead plaintiff. PLEASE CLICK HERE TO JOIN THE CASE AND SUBMIT CONTACT INFORMATION Nature of the Action: Federal securities class acti ...

Core Viewpoint - A class action lawsuit has been filed against Ardent Health, Inc. concerning allegations of securities fraud and unlawful business practices by the company and its officers [2]. Financial Performance - On November 12, 2025, Ardent reported a $43 million decrease in third quarter 2025 revenue due to revised determinations of accounts receivable collectability after transitioning to a new revenue accounting system [3]. - The new accounting system, Kodiak RCA net revenue platform, allows for more precise determination of accounts receivable collectability and recognizes reserves earlier in an account's life cycle compared to the previous framework [3]. - Ardent also cut its 2025 EBITDA guidance by approximately 9.6%, from a range of $575 million - $625 million to $530 million - $555 million, citing persistent industry-wide cost pressures [3]. - Additionally, the company recorded a $54 million increase in professional liability reserves related to recent settlements and ongoing litigation, influenced by broader industry trends [3]. - Following these announcements, Ardent's stock price fell by $4.75 per share, or 33.81%, closing at $9.30 per share on November 13, 2025 [3].